BNP PARIBAS ASSET MANAGEMENT Holding S.A. Reduces Position in Moderna, Inc. $MRNA

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 22.8% during the second quarter, HoldingsChannel reports. The institutional investor owned 93,916 shares of the company’s stock after selling 27,811 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Moderna were worth $2,587,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in MRNA. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new position in Moderna during the 1st quarter worth approximately $28,350,000. Jacobs Levy Equity Management Inc. purchased a new position in Moderna during the 1st quarter worth approximately $28,308,000. Jump Financial LLC grew its stake in Moderna by 5,590.0% during the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after buying an additional 886,567 shares during the last quarter. Invesco Ltd. grew its stake in Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after buying an additional 877,162 shares during the last quarter. Finally, Sessa Capital IM L.P. purchased a new position in Moderna during the 1st quarter worth approximately $21,066,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on MRNA shares. Bank of America lowered their target price on Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a research note on Tuesday, July 22nd. Leerink Partners lowered their target price on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research note on Friday, August 22nd. Wells Fargo & Company reiterated an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Cowen started coverage on Moderna in a research note on Sunday, July 13th. They issued a “hold” rating on the stock. Finally, Citigroup lowered their target price on Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $36.86.

Moderna Price Performance

MRNA opened at $23.56 on Thursday. The business has a 50 day simple moving average of $25.80 and a 200-day simple moving average of $27.15. The stock has a market capitalization of $9.20 billion, a P/E ratio of -3.13 and a beta of 2.02. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $56.69.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.